



 Bristol Myers Squibb®

2027-2028

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM

Letter From Senior Leadership



Dear Prospective Fellow,

On behalf of Bristol Myers Squibb (BMS) and the Ernest Mario School of Pharmacy, we would like to thank you for your interest in the Post-Doctoral Pharmaceutical Industry Fellowship Program. The pharmaceutical industry provides many exciting and dynamic opportunities, and the same is true at BMS in particular.

BMS truly differentiates itself by combining the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company. We never give up in our search for the next innovation that could mean new hope for patients who are urgently seeking new treatment options today. Constantly pushing the boundaries of scientific excellence, our medicines help millions of people in their fight against serious diseases. Focused on addressing areas of significant unmet medical need, we have exciting development programs in areas such as oncology, hematology, immunology, neuroscience, and cardiovascular diseases.

We recognize the importance of social responsibility and the innovative medicines we create. Our belief that “the priceless ingredient of every product is the integrity of its maker,” shines through in how we hold ourselves to the highest standard of integrity. We are not only committed to making a difference in the lives of patients, but also in the global communities where we operate.

BMS places an equal commitment to the development of the individuals who work with us. To meet our mission of helping patients prevail over serious diseases, we are committed to developing a workforce that is diverse, inclusive and representative of the communities in which we operate. We want individuals to bring their authentic selves to work and to use their perspectives to contribute in a unique and meaningful way to our mission. We champion these efforts at the highest levels of our organization to ensure our people are engaged and empowered.

Over the past 30 years, we have been creating a best-in-class fellowship program devoted to preparing unique and highly motivated individuals, like yourself, for a rewarding and successful career in our industry.

On behalf of everyone at BMS, we invite you to strongly consider joining our community of people working together to transform the lives of patients through one of the fellowships we offer with Rutgers, Ernest Mario School of Pharmacy. We wish you the best of luck during the recruitment process.

Sincerely,
Chris Boerner, Ph.D.
Board Chair and Chief Executive Officer



Table of Contents

ABOUT BRISTOL MYERS SQUIBB	4
PROGRAM DESCRIPTION	
Marketed Products & Innovative Pipeline	5
BMS Fellowship Campus Locations	6
Post-Doctoral Program Governance	7-8
RECRUITING OPPORTUNITIES	9
COMMERCIAL	10
US Market Access	11
Commercial Insights & Forecasting	12
Enterprise Competitive Intelligence and Portfolio Analytics	13
CLINICAL	14
Regional Clinical Operations	15
MEDICAL	16
Global Cardiovascular Medical Strategy & US Field Medical Sciences	17
US & Worldwide Medical Strategy: CAR T Cell Therapy	18
US & WW Immunology Medical Strategy	19
WW & US Oncology Medical Strategy	20
US Field Medical Neuroscience and Medical Evidence Generation (MEG)	21
Global Cardiovascular Medical Communications	22
REGULATORY	23
Global Regulatory Strategy	24
US Commercial Regulatory Affairs: Advertising & Promotion	25
BMS FOUNDATION	26
Bristol Myers Squibb Foundation: Global Health Pharmacy Fellowship	27
NON-RECRUITING PROGRAMS	28
LEADERSHIP SPOTLIGHT	29
RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB	30-31
BRISTOL MYERS SQUIBB COMPONENT	32
RUTGERS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM	33



About Bristol Myers Squibb

Our Mission

To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Our Commitment

To our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behavior. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers. As a responsible corporate citizen, we seek to actively improve the health of the communities where we live, work and serve. Around the globe, we promote health equity and seek to promote the health outcomes of populations disproportionately affected by serious disease. We believe our diverse and inclusive culture supports better outcomes for all patients and we seek diversity in all aspects of our business.

Our Biopharma Success

At Bristol Myers Squibb, we uniquely combine the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers' needs, giving maximum priority to accelerating pipeline development, delivering sales growth, and continuing to manage costs. In recent years, we have outperformed most mega pharma companies, diversified companies, and pure biotech companies, having delivered 13 new medicines since 2019, and have a growing registrational portfolio. We are a BioPharma leader with a commitment to patients with serious disease, focused on finding innovative medicines to address unmet medical needs. Having transformed Bristol Myers Squibb into a benchmark BioPharma company, we now stand on the frontier of new possibilities with a commitment to making a meaningful difference in the lives of our patients. Continuous innovation is critical to our BioPharma strategy and is enhanced by our diverse workforce and inclusive culture. Over the years, Bristol Myers Squibb and its employees have received numerous distinguished awards and recognitions. Furthermore, we have the honor of maintaining a perfect score on the Corporate Equality Index and having been named one of the World's Most Admired Companies.

2025 Fast Company Most Innovative Companies List	2025 JUST Capital Companies That Help Women Thrive List	2025 BioNJ Innovator	2025 Age-Friendly Institute CAFE Program Certification	
 Bristol Myers Squibb®				
				
				

Marketed Products & Innovative Pipeline

Bristol Myers Squibb focuses on discovering and developing innovative medicines that address serious diseases in areas of significant unmet medical need. We concentrate our research efforts in the following core therapeutic areas: Oncology, Hematology, Cardiovascular, Immunology, and Neuroscience.

49

**INVESTIGATIONAL
THERAPIES**

[SEE OUR FULL PIPELINE HERE](#)

**Cutting edge technologies
& discovery platforms**

Biologics
Small molecules
Cell therapy
Radiopharmaceuticals

**Therapeutic areas
with unmet needs**

Oncology
Hematology
Cardiovascular
Immunology
Neuroscience

IMMUNOLOGY

ORENCIA®
(abatacept)

SOTYKTU™
(deucravacitinib) 6 mg tablets

NEUROSCIENCE

ZEPOSIA®
(ozanimod) 0.92 mg capsules

COBENFY™
(xanomeline and trospium chloride) capsules
50mg/20mg, 100mg/20mg, 125mg/30mg

CARDIOVASCULAR

Eliquis®
(apixaban) tablets 5mg
2.5mg

CAMZYOS™
(mavacamten) capsules
2.5, 5, 10, 15mg

ONCOLOGY

KRAZATI®
(adagrasib) 200 mg TABLETS

OPDIVO™
(nivolumab)

OPDIVO Qvantig™
nivolumab + hyaluronidase-nvly
SUBCUTANEOUS INJECTION 120 mg + 2,000 units / mL

YERVOY™
(ipilimumab)

Opdualag™
(nivolumab and relatlimab-mbaw)
Injection for intravenous use | 480 mg/160 mg

CELL THERAPY

Breyanzi™
(lisocabtagene maraleucel) SUSPENSION
FOR IV INFUSION

Abecma™
(idecabtagene vicleucel) SUSPENSION
FOR IV INFUSION

HEMATOLOGY

Reblozyl®
(luspatercept-aamt)
for injection 25mg + 75mg

BMS Fellowship, Primary Campus Location

Princeton Pike (PPK)

Lawrenceville, NJ





Post-Doctoral Program Governance

Executive Steering Committee



Melissa Harris, PharmD, RUCIF
Chief of Staff to the Chairman and CEO
Executive Sponsor



Priya Darouian, PharmD, RUCIF
Senior Director, Medical Customer
Experience (CX) Strategy
Head & Steering Committee Lead



Thomas Lehman, PharmD, RUCIF
Executive Director, WW Medical
Rheumatology
Steering Committee Co-Lead

Steering Committee Members



Cathy Merrill, PharmD, RUCIF
Senior Director, Medical
Evidence Generation Team
Lead, Oncology



Matt Lupo, MCIS
Executive Director,
Commercial Regulatory Affairs



Ijeoma Oyetunde, PharmD
Senior Director, PRMT5
Medical Product Lead,
Global Medical Oncology



Austin Bock, PharmD, RUCIF
Associate Director,
Medical Communications,
Cardiomyopathy



Victoria Berger, PharmD, RUCIF
Director, Global Clinical
Science, Immunology



Peter Fendt, PharmD, RUCIF
Director, NEX-T

Second-Year Co-Chief Fellows



Smruti Rajpara, PharmD

Second-Year Fellow

US & WW Medical Strategy: CAR T Cell Therapy



Jessica Priya Saini, PharmD

Second-Year Fellow

Global Regulatory Strategy



Pranay Chinthaparthi, PharmD

Second-Year Fellow

Commercial Business Insights & Analytics



2027-2028

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM





COMMERCIAL

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



US Market Access



Tazche Turner, PharmD

Second-Year Fellow
University of North Carolina,
Eshelman School of Pharmacy



Jordan Bernard, PharmD

First-Year Fellow
University of Connecticut School of
Pharmacy

This two-year fellowship offers the opportunity to join a rapidly-evolving access organization that leads in the industry to ensure patient and provider access to therapy. Within the fellowship program, the Fellow will have the opportunity to gain experience working in multiple components of the organization, with an emphasis in Hematology and Oncology. Through three rotational opportunities, the Fellow will build core foundational marketing skills, develop a comprehensive understanding of drug pricing, payer-provider reimbursement, and patient affordability. Additionally, the Fellow will gain exposure to many experiences and gain valuable insight into tactics and cross-matrix initiatives used to ensure patient access to quality care.

The fellowship is structured in flexible rotations within the core US market access teams which includes Patient Access Support Services, Pricing & Contracting, and Access Strategy. During this program, the Fellow will:

PATIENT ACCESS SUPPORT SERVICES

- Evaluate healthcare policy and market access trends to assess the implications for provider reimbursement and patient affordability
- Develop educational content and support program design initiatives that improve patient and provider access to therapy across medical and pharmacy benefit settings, including reimbursement, access, education, affordability solutions, and customer experience enhancements

PRICING & CONTRACTING

- Understand challenges and business drivers across multiple channels including Payers, Integrated Delivery Networks, Group Purchasing Organizations, and Pathway organizations
- Gain experience in economic modeling to shape pricing strategy for new and existing products based upon shifting marketplace pressures and dynamics

ACCESS STRATEGY

- Contribute to the brand payer strategy by evaluating payer management trends, emerging access influencers, and the evolving competitive landscape
- Interact with HCP marketing, medical strategy, health economics and outcomes research, and market research to develop promotional materials that communicate the value of our products to managed care organizations

ADDITIONAL EXPERIENCES

- Engage in field rides with external stakeholders alongside BMS Field Teams, including Access and Reimbursement Managers, Medical Science Liaisons, and Account Executives
- Participate in potential opportunities with US market access matrix teams such as Oncology Brand Marketing, Policy & Government Affairs, and Global Market Access

Commercial Insights & Forecasting



Pranay Chinthaparthi,
PharmD

Second-Year Fellow
Rutgers University Ernest
Mario School of Pharmacy

This two-year commercial fellowship provides an opportunity for a Fellow to develop foundational expertise across market research and forecasting while supporting strategic decision-making within the Cell Therapy business. The Fellow will gain experience translating customer, market, competitive, and performance insights into actionable recommendations that support brand strategy, business planning, and long-term commercial priorities.

The Fellow will spend the first year in Market Research, focused on Cell Therapy, where they will help identify customer and market insights that inform brand strategy, customer engagement, launch planning, and lifecycle management. In the second year, the Fellow will rotate into Forecasting, also focused on Cell Therapy, where they will support demand, revenue, and scenario-based forecasting to help business stakeholders understand key opportunities, risks, and assumptions. Across both rotations, the Fellow will synthesize primary and secondary data, partner with cross-functional teams, and translate insights into actionable recommendations for senior leaders and business stakeholders.

These rotational opportunities will allow the Fellow to build a strong understanding of how insights, analytics, and forecasting are used to support commercial strategy, performance planning, and data-driven decision-making.

MARKET RESEARCH: CELL THERAPY

- Work closely with cross-functional teams in Marketing, Medical, Sales, Forecasting, Access, and Analytics to understand business opportunities and design market research projects that address key Cell Therapy business questions
- Manage and analyze primary market research projects with vendor partners to generate insights that inform brand strategy, customer engagement, launch planning, and lifecycle management
- Maintain knowledge of market dynamics, customer needs, treatment trends, and the evolving competitive environment to help stakeholders adapt to the dynamic Cell Therapy landscape
- Synthesize primary and secondary data into clear, actionable reports and presentations that guide strategic decision-making across the Cell Therapy business
- Support the development of innovative market research approaches and new ways of gathering customer insights

FORECASTING: CELL THERAPY

- Support development and refinement of Cell Therapy forecasts by integrating market assumptions, demand drivers, treatment dynamics, and stakeholder input
- Partner with Marketing, Market Research, Access, Finance, and other cross-functional teams to align on forecast assumptions, key business questions, and scenario-planning
- Analyze forecast outputs, business performance trends, and key assumptions to help identify opportunities, risks, and drivers of change across Cell Therapy assets and indications
- Contribute to scenario planning and sensitivity analyses to evaluate how changes in market dynamics, launch timing, competitive events, patient flow, access, pricing, or adoption may impact forecast outcomes
- Help communicate forecast insights through clear presentations, dashboards, and summaries that support leadership discussions, planning cycles, and strategic decision-making

The Fellow will develop valuable skills and experiences in identifying business opportunities, translating insights into strategic recommendations, and supporting data-driven planning. The Fellow will also develop transferable skills in project management, vendor management, cross-functional collaboration, analytics, forecasting, and executive-level communication.

Enterprise Competitive Intelligence and Portfolio Analytics

At BMS, the Enterprise Competitive Intelligence and Portfolio Analytics division fuels bold decisions to create a competitive advantage and accelerate growth. This joint two-year fellowship is a unique opportunity for a Fellow to identify insights and work in a team to translate these findings into actionable recommendations for senior management. The Fellow will lead critical projects on cross-functional teams with stakeholders from Marketing, Market Research, Forecasting, Access, Medical Affairs, Global Commercial Strategy, Business Development, and R&D Clinical Development.

The Fellow will spend the first year in Competitive Intelligence and the second year in Portfolio Analytics. While on both teams, the Fellow will synthesize insights from primary and secondary research, analytics, and emerging AI-enabled tools to assess the competitive landscape, identify opportunities and risks, and deliver actionable recommendations to business stakeholders. During their tenure in Portfolio Analytics, the Fellow will also serve as a strategic partner to Global Program Teams, contributing to and facilitating discussions and assessments that lead to well-informed investment decisions at both the opportunity and asset levels. These rotational opportunities will allow the Fellow to help provide strategic partnerships and understand procedures within the Portfolio Strategy organization.

COMPETITIVE INTELLIGENCE

- Monitor and assess the competitive environment, scientific data, market trends, and emerging threats to inform clinical, medical, and commercial strategy
- Synthesize insights from primary and secondary sources to develop actionable recommendations for cross-functional stakeholders and senior leadership
- Deliver real-time analysis of competitor activities, clinical data readouts, regulatory milestones, and market developments, producing insights and deliverables such as competitor alerts, trial readout assessments, competitor timelines and landscapes that translate findings into clear implications and strategic recommendations for stakeholders
- Lead congress intelligence planning and execution, transforming key findings into insights that support brand and therapeutic area priorities
- Partner with stakeholders to identify key business questions, close knowledge gaps, and anticipate future market and competitive scenarios

PORTFOLIO ANALYTICS

- Individual will apply therapeutic area expertise, risk assessment (probability of technical success), and financial analysis to drive the organization toward high-quality investment decisions at the opportunity and asset level using quantitative models and processes, conducting workshops, and facilitating discussions as a strategic partner to the Global Program Team (GPT)
- Implement decision analysis tools and processes (e.g., influence maps, impact scoring cards) to support strategic decision-making in collaboration with cross-functional leaders
- Participate in the facilitation of strategic workshops to help GPTs define frameworks, assess options, and identify key value drivers and trade-offs
- Partner within broader Portfolio Strategy Team in developing methodologies and approaches for contextualizing TA level portfolio decisions and lifetime value



CLINICAL

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Regional Clinical Operations



David Baker, PharmD

Second-Year Fellow
Virginia Commonwealth University
School of Pharmacy

CLINICAL TRIAL MANAGEMENT FELLOWSHIP

This two-year fellowship provides an opportunity to develop expertise in regional clinical trial execution through the role of a Clinical Trial Manager (CTM). The program is designed to evolve with the Fellow, adapting to their interests, strengths, and business opportunities while providing broad exposure to clinical trial management.

The Fellow will gain hands-on experience supporting the planning and execution of Phase I-IV clinical trials at the country level. Key areas of focus include study start-up, trial conduct, patient recruitment, risk management, vendor and site oversight, and cross-functional collaboration. Working closely with internal and external stakeholders, the Fellow will help ensure clinical studies are delivered with quality, compliance, and efficiency.

Throughout the program, the Fellow will build a strong foundation in Good Clinical Practice (GCP), International Council for Harmonization (ICH) guidelines, and country-specific regulatory requirements. They will collaborate with Clinical Scientists (CSs), Clinical Trial Physicians (CTPs), Global Trial Managers (GTMs), Regional Delivery Leads (RDLs), Clinical Research Associates (CRAs), Data Management, Medical Affairs, Trial Supply, vendors, and investigator sites to understand how clinical trials are managed from feasibility through close-out.

The fellowship may also include a rotation within Clinical Development, offering additional insight into the broader drug development process and the connection between regional operations and clinical strategy. While the following areas represent the core learning objectives, the fellowship experience will be tailored to the Fellow and may evolve throughout the two years.

During the Fellowship, the Fellow will:

CLINICAL TRIAL START-UP & FEASIBILITY

- Support country and site feasibility assessments, study start-up activities, and coordination with local and global study teams
- Assist with the review and validation of study materials, including protocols, Informed Consent Forms (ICFs), and patient-facing documents
- Gain experience with site activation activities, from Clinical Trial Package (CTP) development through Site Initiation Visit (SIV) preparation and execution

STUDY CONDUCT & OVERSIGHT

- Participate in country-level study oversight, helping to deliver studies on time, within budget, and in alignment with quality and enrollment goals
- Contribute to patient recruitment planning, study tracking, and risk mitigation efforts
- Develop proficiency with clinical trial systems, including Clinical Trial Management Systems (CTMS), electronic Data Capture (eDC), and electronic Trial Master Files (eTMF), to support inspection-ready study documentation

COMPLIANCE, RISK MANAGEMENT & INSPECTION READINESS

- Learn to identify, escalate, and resolve operational risks and study issues
- Support activities related to monitoring follow-up, query management, and database lock readiness
- Gain exposure to audit and inspection preparedness, Health Authority interactions, Corrective and Preventive Action (CAPA) planning, and submissions to Institutional Review Boards (IRBs)

CROSS-FUNCTIONAL LEADERSHIP & STAKEHOLDER ENGAGEMENT

- Strengthen communication, project management, and problem-solving skills through collaboration with investigator sites, vendors, IRBs, and internal cross-functional teams
- Participate in training, mentoring, and process improvement initiatives
- Explore stretch assignments and learning opportunities across the broader clinical development organization as the fellowship progresses



MEDICAL

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Global Cardiovascular Medical Strategy & US Field Medical Sciences



Emily Tran, PharmD

Second-Year Fellow
University of Arizona R.
Ken Coit College of Pharmacy



Shiloh Sweat, PharmD

First-Year Fellow
UNT Health College of Pharmacy

This two-year fellowship provides an opportunity to develop expertise in strategic in-house medical affairs and field medical activities. The Fellow will acquire cardiovascular disease state knowledge and master the BMS cardiovascular product portfolio. Additionally, the Fellow will work on high priority projects and initiatives aligned with the Medical Plan to support impactful HCP interactions. The Fellow will develop leadership and communication skills through collaboration across the Global Medical matrix teams and other key partners. Key activities and learnings will include:

MEDICAL STRATEGY

- Participate in the Global Medical matrix team to support strategic planning based on the unmet medical needs from the perspectives of patients, providers, and payers
- Support the execution of the Medical Strategy tactical plan by working across matrix teams (Marketing, Field Medical, Medical Communications, Advocacy, Clinical Development, Legal and Regulatory) as well as with alliance partners
- Collaborate with cross-functional medical team members to deliver on key medical initiatives, including advisory boards, proactive messaging, reactive medical communication, and publication strategy
- Support development of medical training materials for sales representatives and deliver medical presentations at sales training sessions
- Contribute towards congress strategy and lead the execution of National Congress planning activities as part of the CV Medical Plan

FIELD MEDICAL SCIENCES


- Complete MSL trainings and certification process for the CV profile
- Engage thought leaders in scientific discussions during field-based activities with CV MSLs
- Assess/identify gaps in MSL resources and collaborate with medical strategy on the development of MSL scientific resources and trainings
- Collaborate with the Field Medical Leadership Team to support development and implementation of field medical priorities
- Contribute to scientific congress Field Medical initiatives and planning
- Develop an understanding of clinical trial site maintenance and the MSL educational role

US & Worldwide Medical Strategy: CAR T Cell Therapy



Smruti Rajpara, PharmD

Second-Year Fellow
Rutgers University Ernest
Mario School of Pharmacy



Siddharth Pant, PharmD

First-Year Fellow
Thomas Jefferson University
College of Pharmacy

Cell therapy is one of the most exciting and rapidly evolving frontiers in medicine today. BMS has both approved products and a deep pipeline in this space, with cell therapy continuing to be studied across autoimmune disorders, neuro-inflammatory conditions, and hematologic malignancies. This is a two-year fellowship in which the Fellow will build experiences across the full range of cell therapy Medical Affairs, with exposure to emerging modalities such as autologous and in vivo CAR T cell therapies. Throughout the fellowship, the Fellow will gain hands-on and leadership experience across US and Worldwide Medical Strategy teams and is expected to participate in several key market events. This program will equip the Fellow to lead medical projects independently, navigate a global matrix, and turn emerging clinical evidence into actionable strategy across therapeutic areas.

MEDICAL STRATEGY

- Participate in strategic planning with collaborators from across the US and Worldwide Medical matrix teams to address unmet medical needs from the perspectives of patients, providers, and payers
- Lead key medical projects and activities including data generation, content development, training, insight reporting, advisory boards, and congress planning in partnership with the broader medical matrix team (Field Medical, Medical Communications, Medical Evidence Generation, Medical Education, Sales, Marketing, Outcomes Research, Promotional Review, Legal, and Global Pharmacovigilance & Epidemiology)
- Participate in projects unique to cell therapy, including efforts to support ecosystem evolution that enable patient access to therapy across various clinical practice settings
- Engage US and International Key Opinion Leaders through advisory boards, steering committees, and congresses to inform and elevate BMS strategy
- Experience applications of cell therapy across therapeutic areas, including but not limited to autoimmune disease, neuro-inflammatory conditions, and/or hematologic malignancy



US & WW Immunology Medical Strategy



Mariam Mckee, PharmD

Second-Year Fellow,
University of South Florida Taneja
College of Pharmacy



**Satchell Medé Pacheco,
PharmD**

Second-Year Fellow
Florida A&M University College
of Pharmacy and Pharmaceutical
Sciences, Institute of Public Health

This two-year fellowship provides an opportunity to work in one of the most exciting and competitive areas of immunology research and pharmaceutical development today: Rheumatology. Individuals participating in this fellowship will gain a broad understanding of Medical Affairs through both participatory and leadership experiences from the perspective of both the US and Worldwide Medical Strategy Teams. This fellowship will provide the opportunity to work across both the Medical Strategy and Medical Communications functions within the Global Immunology organization. During the fellowship, the Fellow is expected to experience several important market events including pre- and post-launch support in rheumatology following several phase 3 data read outs. The Fellow will learn how to communicate key clinical and economic data across various channels to inform healthcare decision making. Graduates of this fellowship have gone on to lead successful careers at various pharmaceutical companies in multiple aspects of Medical Affairs including Medical Strategy, Scientific Communications, Clinical Development, Medical Science Liaison, Medical Information, and Independent Medical Education.

US MEDICAL STRATEGY – RHEUMATOLOGY

- Participate in strategic planning with the US Medical Matrix Team based on unmet medical needs from the perspectives of patients, providers, and payers
- Lead medical projects in partnership with the broader medical matrix team members (Field Medical, Medical Communications, Independent Medical Education, Sales, Marketing, Outcomes Research, Promotional Review Team, Legal, and Global Pharmacovigilance & Epidemiology)
- Lead and participate in key aspects of medical affairs including content development, training, insight reporting, advisory boards, and congress planning
- Conduct medical review of promotional and non-promotional materials in collaboration with Legal, Regulatory, and Marketing teams

WORLDWIDE MEDICAL STRATEGY – RHEUMATOLOGY

- Lead development and execution of the Global Medical Plan in partnership with key international market teams (eg, US, EU, Asia-Pacific), Clinical Development, & Commercial
- Engage International Key Opinion Leaders via advisory boards, steering committees, and international conferences to inform and elevate BMS strategy
- Identify educational opportunities among Rheumatologists and execute plans to fulfill them; e.g., disease education, pathway materials, conference symposia, review articles
- Develop integrated data generation plans and review/approve investigator sponsored research proposals to inform appropriate use of BMS medicines and fulfill unmet medical need

WW & US Oncology Medical Strategy



Mia Como, PharmD, RPh

Second-Year Fellow
University of Pittsburgh School
of Pharmacy



**Joseph Noetzel, PharmD,
RPh**

First-Year Fellow
Roosevelt University College of
Science, Health and Pharmacy

Medical Strategy is where scientific and clinical knowledge meet strategic application. This two-year fellowship provides an opportunity to support the development and execution of Worldwide and US Oncology Medical Strategy and other medical activities. During the first year in Worldwide Medical Oncology, the Fellow will focus on developing the global strategy in a wide array of tumor types through collaborative efforts with BMS regional offices around the world. During the second year in US Medical Oncology, the Fellow will focus on developing and executing the US strategy for the success and continued support of a wide range of indications through medical engagements, conferences, and launches. Throughout these two years, the Fellow will gain exposure to various stakeholders and develop leadership skills by supporting and leading medical initiatives in collaboration with the Worldwide and US cross functional matrix teams (e.g., Clinical Development, Clinical Operations, Regulatory, Medical Communications, Field Medical, Commercial, HEOR, Competitive Intelligence, Market Access, and more). Additionally, the Fellow will have opportunities to collaborate closely with the patient advocacy team. This includes partnering to present and execute patient advocacy advisory boards, attending patient advocacy meetings at congresses, and developing various patient-related tactics. This will provide the Fellow with a deep understanding of how our work directly impacts patients' lives.

WORLDWIDE MEDICAL STRATEGY

- Gain experience in the development of a strategically-aligned Global Medical Plan based upon unmet medical need by collaborating with a cross functional, multi-regional (i.e., US, EU, Asia-Pacific) Worldwide Medical matrix team
- Engage with external Thought Leaders in an effort to exchange and gather scientific and clinical knowledge through investigator meetings, advisory boards, Thought Leader Engagements (TLEs), publication planning, and congresses
- Lead the execution of medical deliverables that are closely aligned with the strategic Global Medical Plan, including National and International Congress planning for activities such as advisory boards, symposia, and TLEs
- Collaborate with BMS country-specific medical colleagues to collect field insights that will support strategic planning and tactical execution
- Actively participate in the review and approval process of Investigator Sponsored Research proposals that are aligned with the data generation plan detailed in the Global Medical Plan

US MEDICAL STRATEGY


- Participate in key medical activities such as medical advisory boards, Field Medical resources and trainings, Congress planning (e.g., ASCO, ASCO GI), reactive content, and aid in the development of the communication strategy, including publications
- Collaborate with US Medical matrix teams (e.g., Field Medical, Evidence Generation, Patient Advocacy, Medical Education, and Congress Management) to support planning and delivery of medical objectives based on unmet medical needs
- Collaborate and communicate with US Commercialization & Access organizations to integrate medical perspectives into the commercialization process and ensure appropriate alignment between commercial and medical plans
- Engage with external thought leaders and scientific experts to assess unmet medical needs to develop appropriate medical strategies

US Field Medical Neuroscience and Medical Evidence Generation (MEG)



Mitchel Haykal, PharmD

Second-Year Fellow
Binghamton University School
of Pharmacy and Pharmaceutical
Sciences



Valerie Malinsky, PharmD

First-Year Fellow
West Virginia University
School of Pharmacy

The US Field Medical Neuroscience and Medical Evidence Generation (MEG) position is a two-year fellowship that will provide an opportunity to gain expertise in multiple dimensions of the medical affairs function in the neuroscience space. During their first year, the fellow will join the US Field Medical Neuroscience team and participate in key projects, critical to the success of new product/indication launches and currently approved products across assets within the Neuroscience organization. The fellow will gain an appreciation for core Field Medical competencies spanning field training, resource creation, operations, and thought leader (TL)/ investigator engagement. The fellow will have the opportunity to learn the intricacies of the MSL role via training, field rides, and scientific congress attendance. In their second year, the fellow will join the MEG team and contribute to the development and implementation of the Integrated Evidence Plan (IEP) and interact with the different modalities of evidence generation (investigator-sponsored studies, interventional and noninterventional company-sponsored trials, collaborative research, and exploratory analysis among others). The fellow will focus on the science and strategy of MEG generated studies, learning various aspects of clinical studies (Phase IIIb/IV) including study design, initiation, maintenance, and closure activities.

US FIELD MEDICAL NEUROSCIENCE

- Serve as an integral part of the Field Medical Neuroscience Strategy and Operations team and key contributor for field medical planning, stakeholder communications, MSL training, and launch/life-cycle management projects
- Gain product and therapeutic expertise via MSL trainings, validations, and assessments in Neuroscience as foundational knowledge to apply to various projects and activities
- Collaborate with home office medical, medical learning, and field matrix teams to assist in the development of training initiatives and medical resources, including opportunity for stretch projects with these teams
- Contribute on innovative tactics and/or platforms to elevate MSL development and productivity in the field including resource launches, technology updates, and serving as point of contact for MSL troubleshooting
- Interact with external TLs throughout the fellowship year on field rides with MSLs and activities at scientific congresses. The Fellow will have the opportunity to accompany MSLs on field rides and virtual interactions to gain an understanding of diverse experiences with TLs and study investigators. At congresses the fellow will experience the responsibilities of a MSL including presenting BMS data, competitive intelligence coverage, medical booth support, and gathering insights from thought leaders
- The fellow will collaborate across the cross-functional matrix team, including commercial, medical affairs, and other key stakeholders, to align on strategic priorities and drive cross-functional excellence in the field

MEDICAL EVIDENCE GENERATION (MEG)

- Support the development, tracking and maintenance of Integrated Evidence Plans (IEPs) that reflect asset strategy, market priorities and medical evidence generation support in partnership with the Global Medical Disease Team and cross-functional teams including Global Drug Development (GDD), Translational Development, Health Economics and Outcomes Research (HEOR), and others
- Co-develop Areas of Interest (AOI) based on key open data questions (ODQ) identified in the IEP with market input in collaboration with the Global Medical Disease Teams
- Assist with the scientific aspects of the ongoing Investigator-sponsored Research (ISR) book of work and interface with all key stakeholders across the matrix
- Conduct regular book of work reviews in partnership with GDO (Global Development Operations) with key medical and development stakeholders, under their remit. Identify studies at risk for failing to meet timelines and negotiated mitigation plans with key internal stakeholders and investigators
- Assist in the reviews of concepts through RFP (Request for Proposals) process, as appropriate, including providing context for ongoing book of work, area of interest development, and upcoming data read-outs
- On MAST studies: drive the development of study design, protocol development, and study execution by providing clinical research expertise, presenting protocol specific topics, responding to health authority requests, and supporting the team at various therapeutic area conferences
- On CRCs (Clinical Research Collaboration): lead strategic alignment, relationship management, and study execution oversight in close collaboration with external investigators to align with the IEP and BMS's strategic imperatives
- Support the study team in comprehensive clinical data review and analysis via available data review tools such as patient profiles, data review reports and data listings

Global Cardiovascular Medical Communications



Devin John, PharmD

Second-Year Fellow
St. John's University College
of Pharmacy

This two-year fellowship provides an opportunity to work across the Medical Affairs functional areas within the Cardiovascular Global Medical organization. The Fellow will learn to communicate key clinical and real-world evidence across channels to inform healthcare decision-making, gaining experience in generating strategic, prioritized scientific publications, content, and medical education for HCPs and patients. The Fellow will become adept at planning and executing scientific communication deliverables, including journal publications, congress presentations, reactive and proactive slide decks, standard response documents, and dossiers. A rotational opportunity within Medical Strategy may also be offered, providing hands-on exposure to strategic planning based on unmet medical needs and knowledge gaps. The rotation may include support of key strategic initiatives such as advisory boards, educational needs assessments, and data generation plans. The position cultivates critical thinking and leadership through cross-functional collaboration with internal and external stakeholders (e.g., Medical Strategy, HEOR, Field Medical, Field HEOR, Medical Information, Clinical Development, Regulatory, and third-party vendors). Key activities and learnings include:

SCIENTIFIC PUBLICATIONS

- Gain experience through collaboration with Global Medical Strategy, HEOR, and other stakeholders in developing strategic and impactful clinical and HEOR publications for BMS assets
- In collaboration with Global Medical Strategy, external authors, and appropriate internal stakeholders, develop publications adhering to BMS publication standards including abstracts, congress presentations, and manuscripts focused on disease burden, unmet medical needs, and the clinical and economic value of BMS assets
- Lead the execution of publication plans and develop skills for managing stakeholders, both external and internal, in multiple functional areas to ensure strategic alignment of the publication plans

GLOBAL SCIENTIFIC CONTENT

- Understand the unique information needs of HCPs and patients to ensure strategic and prioritized information delivery
- Collaborate with Global Medical Strategy, HEOR, medical field teams, and other stakeholders to ensure development of fair-balanced scientific content with the highest degree of medical integrity, accuracy, and clinical relevance
- Lead content creation for deliverables spanning clinical, economic, and real-world evidence for BMS medicines, including AMCP dossiers, Medicaid and guideline submissions, reactive slide decks, standard response documents, FAQs, and medical information responses





REGULATORY

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Global Regulatory Strategy



Jessica Priya Saini, PharmD

Second-Year Fellow

Fairleigh Dickinson University School of
Pharmacy and Health Sciences

This two-year fellowship in Global Regulatory Strategy provides the opportunity to develop a broad understanding of the role of regulatory strategy within the drug development process. The Fellow will obtain direct experience and exposure to products at various stages of development and will learn important considerations for working with key regulatory agencies such as FDA and EMA. Depending on interest and the availability of opportunities, the Fellow may be able to collaborate on optional projects with other regulatory disciplines, such as Global Regulatory Labeling, Commercial Regulatory Affairs, or Global Regulatory Policy.

During this program, the Fellow will:

- Participate in the development of global regulatory strategies supporting development, approval, and maintenance of drugs and biologics
- Contribute to identification and assessment of regulatory risks and their mitigation
- Participate in planning and preparing for Health Authority (HA) interactions and assessing the impact of HA feedback on an asset's development plan
- Draft submission documents, including for INDs, NDA/BLAs, and expedited regulatory designation requests
- Conduct regulatory intelligence research to inform development program strategy and decision-making
- Manage responses to Health Authority queries
- Collaborate with matrix team members to identify solutions that meet regulatory requirements as well as commercial objectives
- Partner with Global Regulatory Policy team to evaluate evolving regulatory topics



Elissa Izumi, PharmD

First-Year Fellow

UNC Eshelman School of Pharmacy



US Commercial Regulatory Affairs: Advertising & Promotion



McKenzie Rolle, PharmD

First-Year Fellow

UNC Eshelman School of Pharmacy

The US Commercial Regulatory Affairs group at Bristol Myers Squibb provides strategic regulatory guidance within the company on the Food and Drug Administration (FDA) advertising and promotion regulations to support good business practices. The regulatory advice is provided to the marketing organization to ensure the highest level of ethics and integrity in the promotion of Bristol Myers Squibb products. The group collaborates with a variety of functions including Marketing, Medical Affairs, Legal, Global Labeling, Managed Markets, Global Regulatory, and Safety. The Fellow will be assigned to a primary therapeutic area.

Key activities and learnings will include:

- Gaining an understanding of and ensuring consistency between key federal regulations and Bristol Myers Squibb policies
- Analyzing the impact of FDA Office of Prescription Drug Promotion (OPDP) compliance actions and assessing the regulatory implication to commercial activities
- Assisting in the regulatory review of proposed promotional materials and programs created by Marketing, Sales, or Corporate Affairs and submissions to OPDP
- Collaborating with matrix team members to advise on the development of marketing campaigns that meet regulatory requirements as well as commercial objectives





BMS FOUNDATION

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM

Bristol Myers Squibb Foundation: Global Health Pharmacy Fellowship



Odinaka Oranekwu,
PharmD, RPh

Fellow
Howard University College
of Pharmacy

The Bristol Myers Squibb Foundation's (BMS Foundation), an independent charitable organization, is focused on advancing health equity and dedicating its mission to improving global health. By empowering local communities to create lasting impact, the BMS Foundation invests in capacity building and health systems strengthening programs to expand access to care for medically underserved populations. Through its strategic grantee partners and locally led solutions, the BMS Foundation advances innovative approaches that ultimately improve patient outcomes. The program, offered through Rutgers University, Ernest Mario School of Pharmacy, requires the Fellow to spend approximately six months in Sub-Saharan Africa with the BMS Foundation Adult Cancers program team to build pharmacology capacity and transfer skills to partner organizations. Activities may include:

- Training pharmacy and other healthcare professionals in disease state management and pharmacotherapy
- Developing clinical practice protocols focused on the management of cancer in low- and middle-income countries (LMICs)
- Assisting grantee partners in LMICs with developing cancer surveillance registries that collect data and inform treatment recommendations
- Gaining exposure to project implementation and management at global health field sites
- Engaging community members and organizations through outreach to help improve health outcomes

The Fellow will then complete the remainder of the program in Lawrence Township, NJ and New York City, NY developing a grant management and operations skill set through the US Adult Cancers portfolio and/or other BMS Foundation initiatives (including the Brain Health portfolio in the United States, the Adult Cancers portfolios in Brazil and India, and the clinical trials pillar). Activities may include:

- Supporting end-to-end grant management activities to gain greater insight into health philanthropy within the pharmaceutical industry setting
- Researching issues for the development of grant program strategies
- Providing expert review and technical assistance for pharmacy-related issues
- Connecting project goals with policy and advocacy advancement

As a Rutgers adjunct faculty through the Rutgers University Ernest Mario School of Pharmacy, there will be opportunities for the Fellow to enhance their experience through scholarship, publication, teaching and maintenance of clinical skills.

APPLICATION REQUIREMENTS:

Applicants can pre-schedule an interview at the ASHP Midyear Clinical Meeting through the Personnel Placement Service (PPS). Requirements include: a PharmD from an ACPE-accredited institution, completion of a PGY-1 residency or equivalent clinical experience is strongly preferred, curriculum vitae, three letters of recommendation, letter of intent addressing your interest in global/public health and long-term plans, and willingness to relocate to Sub-Saharan Africa for six months.

Non-Recruiting Programs



US & WW CAR T MARKETING AND COMMERCIAL
Daniel Fuchs, PharmD
 First-Year Fellow
 Purdue University College of Pharmacy



POLICY & PATIENT ADVOCACY
Stephanie Cheng, PharmD, MPH
 First-Year Fellow
 University of Wisconsin-Madison School of Pharmacy



US & WW HEMATOLOGY MEDICAL STRATEGY
Justine Khalil, PharmD
 Second-Year Fellow
 Rutgers University Ernest Mario School of Pharmacy



US HEMATOLOGY MEDICAL STRATEGY
Lily Turner, PharmD
 First-Year Fellow
 University of Pittsburgh School of Pharmacy



WW HEMATOLOGY MEDICAL COMMUNICATIONS AND MEDICAL STRATEGY
Mennah Alkaissi, PharmD
 First-Year Fellow
 UNC Eshelman School of Pharmacy



US FIELD MEDICAL: ONCOLOGY & HEMATOLOGY
Justin Adedinsewo, PharmD, MS
 First-Year Fellow
 Temple University School of Pharmacy



GLOBAL ONCOLOGY MEDICAL EDUCATION & COMMUNICATIONS
Yasmine Ibrahim, PharmD
 First-Year Fellow
 University of Florida College of Pharmacy



GLOBAL DRUG DEVELOPMENT: HEMATOLOGY
Justine Del Prado, PharmD
 Second-Year Fellow
 Rutgers University Ernest Mario School of Pharmacy



GLOBAL DRUG DEVELOPMENT: HEMATOLOGY
Julia Sherman, PharmD
 First-Year Fellow
 University of Michigan College of Pharmacy



GLOBAL DRUG DEVELOPMENT: ONCOLOGY
Marvellous Olowookere, PharmD, MS
 First-Year Fellow
 The Ohio State University College of Pharmacy



GLOBAL DRUG DEVELOPMENT: CELL THERAPY
Zuzanna Strapoc, PharmD
 First-Year Fellow
 University of Illinois College of Pharmacy

Leadership Spotlight



Melissa Harris, PharmD, RUCIF

Executive Sponsor
Chief of Staff to the Chairman and CEO
Fellowship Year 2001-2002

Bristol Myers Squibb is a great company for pharmacists who are wanting to enter the pharmaceutical industry. The company recognizes the value of the unique skill set, training, and experience that enables pharmacists to excel and rise to important management and leadership roles. The diversity and cohesiveness of our PharmD program, and our associated pharmacy community at Bristol Myers Squibb, provides an exceptional experience of seeing, doing, and teaching, which readily prepares our Fellows/Residents to become future leaders within both our Medical and Commercial organizations. As leaders at Bristol Myers Squibb, we appreciate the importance of attracting these talented individuals to fulfill the Bristol Myers Squibb Company mission of helping patients prevail over serious diseases. The Rutgers PharmD Fellowship Program is clearly an important part of our talent development strategy and is key to building and cultivating an innovative and diverse workforce at Bristol Myers Squibb.



Priya Darouian, PharmD, RUCIF

Head & Steering Committee Lead
Senior Director, Medical Customer Experience (CX) Strategy
Fellowship Year 2003-2004

The Bristol Myers Squibb fellowship program has provided me with a solid foundation that prepared me for a successful career in the pharmaceutical industry. As a Fellow, I was an integral part of my team and was provided with a breadth of experiences. My preceptors and mentors were truly invested in my career growth and development. The experiences and friendships I have gained throughout my fellowship and current role are invaluable and will last me a lifetime. The program provides you with the necessary tools and opportunities you need to lead you on a path towards a rewarding career. I am proud to be a part of an organization that has a commitment and passion for patients.



Thomas Lehman, PharmD, RUCIF

Steering Committee Co-Lead
Executive Director, WW Medical Rheumatology
Fellowship Year 2012-2014

Selecting a fellowship at BMS was one of the best decisions I made to jump start my career during the fellowship interview and selection process. As a company with both a people and patient centric culture, a career at BMS for me has meant some of my proudest moments have had an impact for both patients and my career. Over a decade later I look back on my time and think about the people both in the fellowship community and beyond who have helped me succeed and contributed to my professional development. I can recommend no better place to both start and grow your career.

Bristol Myers Squibb Fellowship Alumni

Medical

Alejandro Nava – Senior Manager, US GI & GU Portfolios
Alex Kayal – Senior Manager, Global Medical Affairs, Sjogren's Disease
Antonia Christodoulou – Director, Global Systemic Lupus Erythematosus
Austin Bock – Associate Director, Medical Communications, Cardiomyopathy
Caitlin Henley – Associate Director, WW Medical Upper GI
Carmelo Alonso – Director, US Myelodysplastic Syndrome and Myelofibrosis
Catherine Merrill – Senior Director, MEG Team Lead, Oncology
Chris Higgins – Associate Director, WW Medical Affairs, Cell Therapy Autoimmune
Corey Rantz – Associate Director, US Women's Cancers
Corey Ritchings – Executive Director, Medical Evidence Generation, Oncology
Dorothy Zissler – Director, US Medical Schizophrenia, Psychiatry
Jaime Bunn – Senior Director, Worldwide Medical Immunology & Cardiovascular, Medical Communications
Jagruti Amin – Associate Director, Pan-Tumor/Biomarker/SC PreP
Joseph Kosto – Associate Director, Global Biomarkers
Kaleen Barbary – Director, Medical Communications, Neurology
Karandeep Singh – Associate Director, US Medical Learning, Cardiovascular
Max Prokopovich – Director, Global Thoracic Targeted Therapies
Nabomita Thomas – Senior Director, WW Cell Therapy Portfolio Strategy
Pavit Singh – Senior Director, US Multiple Myeloma Portfolio
Priya Darouian – Senior Director, Medical Customer Experience Strategy (CX) Strategy
Rebecca Dierckes – Director, MEG Lead Hematology, Medical Evidence Generation
Ruchi Shah – Associate Director, Multiple Myeloma, US Medical Cell Therapy
Sam Pike – Associate Director, Global Medical Affairs, US Iberdomide
Samantha Pomponi – Director, US Autoimmune Cell Therapy Medical Affairs
Sirisha Neti – Senior Manager, Medical Excellence and External Engagement, US Medical Cell Therapy
Swara Kasbekar – Director, Global Medical Oncology, IO Thoracic and Head & Neck Cancers Lead
Thomas Lehman – Executive Director, WW Medical Rheumatology
Tim Jurasik – Senior Manager, Global Medical Oncology, US Myeloid
Trixia Camacho – Vice President, MEG Oncology Head, Cross-Portfolio Excellence & MEG Alliances
Vincent Tran – Associate Director, US Medical, Cell Therapy, PreP
Will Jackson – Director, MEG Lead Neuroscience, Medical Evidence Generation

Field Medical

Asia Ridley – Medical Science Liaison, Oncology
Daniel Dilanji – Regional Associate Director, US Field Medical Neurology
Elaine Marji – Medical Science Liaison, Cardiovascular
Karan Verma – Senior Medical Science Liaison, Neurology
Katherine Sprague – Director, US Field Medical Portfolio Engagement Strategy, Cardiovascular
Marie Labib – Medical Science Liaison, Myeloid
Mike Zatkos – Medical Science Liaison, Cardiovascular
Ryan Kendra – Medical Science Liaison, Rheumatology
Somtochukwu Egbuonu – Medical Science Liaison, Neurology
Sydney Ross – Medical Science Liaison, Rheumatology
Teena John – Senior Medical Science Liaison, Neurology
Tia Belvin – Medical Science Liaison, Cardiovascular
Zack Inge – Regional Associate Director, US Field Medical Cardiovascular, Milvexian

BMS Foundation (Corporate Philanthropy)

Mason Chiang – Associate Director, BMS Foundation
Ornesha Watson – Associate Director, BMS Foundation

Commercial

Anthony Salvatore – Director, Global Commercial Strategy Oncology – BioNTech/Solid Tumor
Chloe Thomas – Associate Director, Cardiovascular Accounts & Customer Engagement
Christine Ghobrial – Director, Oncology Commercial Strategy, GI
Christy Wong – Associate Director, HCP Marketing, Reblozyl
Evelyn Abramson – Associate Director, HCP US Marketing, Neuroscience
Frances Sousonis – Associate Director, US Milvexian, HCP Marketing

Jade Hoang – Director, Global Commercial Strategy, Admilparant
Jake Kinley – Senior Therapeutic Area Specialist, Oncology
Josh Linton – Director, Oncology Commercial Strategy, Thoracic and Head & Neck
Justin Balint – Senior Director, Commercialization Strategy & Operations
Lindsey Prima – Director, Oncology Commercial Strategy, GU
Nina Johnson – Associate Director, US Multiple Myeloma Cell Therapy Marketing
Peter Fendt – Director, NEX-T
Sana Mansuri – Senior Manager, CAR T Customer Insights & Engagement
Sharmaine Cubelo – Senior Product Manager, Opdivo Qvantig Patient Marketing
Spencer Heath – Director, Customer Strategy, CAMZYOS

Market Access & Pricing

Amie Lette – Associate Director, Patient Access Marketing
Emily O'Neill – Associate Director, Professional Marketing, CAMZYOS
Jennifer Liu – Director, Global Commercial Strategy, Milvexian
Josh Dadural – Associate Director, US Access Strategy, Oncology
Prianka Singh – Director, Global Launch Strategy, Oncology

Regulatory Affairs

Alexander Cheung – Associate Director, US Commercial Regulatory Affairs
Ashley Kelleher – Senior Manager, Global Regulatory Strategy, Neuroscience
Christine Alonso – Senior Director, US Commercial Regulatory Affairs, Oncology
Elsa Pan – Senior Director, US Commercial Regulatory Affairs, Immunology/CV/Mature Brands
Gabriel Santos – Senior Manager, Advertising and Promotion, Commercial Regulatory Affairs
Jessica Zhu – Senior Manager, Global Regulatory Strategy, Oncology
Kiri Anderson – Associate Director, Advertising and Promotion Commercial Regulatory Affairs, Oncology
Roshan Rao – Senior Manager, Commercial Regulatory Affairs
Sarah Aly – Associate Director, Commercial Regulatory Affairs
Sekayi Mushonga – Vice President, Global Regulatory Strategy, Immunology
Trushna Shah – Director, Regulatory Affairs, Immunology & Neuroscience
Vaidehi Patel – Senior Manager, Global Regulatory Strategy
Yen Krystal Miao – Associate Director, US Commercial Regulatory Affairs

Clinical

Amy Kim – Director, Global Clinical Scientist, Late Hematology, Oncology, & Cell Therapy
Andrew Mettias – Associate Director of Clinical Science, RayzeBio
Brenda Yuan – Associate Director, Senior Clinical Scientist, Cell Therapy
Brielle Carramusa – Senior Manager, Global Clinical Science, Neuroscience
Lana Mudarris – Associate Director, Clinical Scientist, Cardiovascular
Maha Elgohail – Associate Director, Global Clinical Science, Cardiovascular
Melissa Harris – Chief of Staff to the Chairman & CEO
Nicholas Favatella – Senior Director, Global Clinical Science, Cardiovascular
Nishanth Viswanath – Associate Director, Clinical Scientist, Oncology
Sandhya Balachandar – Senior Director, Global Clinical Development, Immunology
Victoria Berger – Director, Global Clinical Science, Immunology
Victoria MacLelland – Senior Manager, Global Clinical Science, Neuroscience
Yasmin Pirestani – Senior Manager, Global Clinical Science, Neuroscience

Business Development & Alliances

Matt Bunn – Executive Director, Mergers & Acquisitions and Business Development & Licensing
Monica Azer Anis – Director, Business Development, Global Alliances

HEOR

Alexandra Kaiser – Director, US Field HEOR Scientist, National Accounts

Policy & Advocacy

Aakash Patel – Director, Global Policy Strategy
Alexis Glenn – Senior Manager, Alliance Development
Chinenye Agim – Senior Manager, Research and Drug Development Advocacy Engagement
Shailee Gusani – Associate Director, US Policy & Research

ALUMNI

From Other RPIF Fellowship Companies

Medical

Alex Agyei Marfo (Pfizer) – Associate Director, US Medical Affairs, Multiple Myeloma
Amber Griffies (Roche) – Director, Worldwide Medical Oncology, Medical Communications
Hiba Malik (J&J) – Associate Director, Melanoma/Product Design and Delivery/Izabren, Global Oncology Strategy & Operations
Irfan Tejani (Sanofi) – Executive Director, Worldwide Medical, Medical Product Lead, GU
Natanya Candelario (Roche) – Senior Director, Global Health Equity
Omama Zubairi (Daiichi Sankyo) – Director, Medical Scientist, US Medical Oncology, GI
Ralu Vlad (Roche) – Senior Vice President, Head of Medical Evidence Generation
Sapna Patel (Novo Nordisk) – Associate Director, Worldwide Medical Oncology, Medical Education
Shalon Jones (Dr. Reddy's Laboratories) – Senior Director, Global Medical Oncology Strategy & Operations

Field Medical

Samantha Kaufman (J&J) – Senior Medical Science Liaison, Oncology
Sheiva Khavari (Roche) – Executive Medical Science Liaison, Rheumatology–Dermatology

Commercial

Akash Lal (Nevakar) – Associate Director, HCP Marketing, SOTYKTU PSA
Alberta Drake (Daiichi Sankyo) – Director, Customer Insights & Engagement- CAR T MM
Amanda Bright (Novartis) – Director, Marketing, Myeloid Marketing
Brittney Rule (Bayer) – Director, Neuroscience Integrated Growth Strategy & Digital Acceleration
Jessica Cairns (Roche) – Senior Vice President, Head of Cell Therapy Commercial
Nora Khalil (J&J) – Associate Director, Marketing-US Oncology

Market Access & Pricing

Joseph Lee (J&J) – Director, Global Market Access, Early Assets & Business Development, CV & Immunology
Lucy Eichenblatt (J&J) – Senior Director, Global Access Strategy Integration, Oncology
Parth Vashi (Bayer) – Director, Global PASL Immunology and Neuroscience

Regulatory Affairs

Akshay Patel (Novartis) – Associate Director, Commercial Regulatory Affairs
Andro Shenouda (Merck) – Senior Director, Team Leader, Global Regulatory Sciences, Oncology
Angela Tang (Roche) – Associate Director, Global Scientific and Regulatory Documentation
Charles Frost (Roche) – Senior Director, Global Scientific and Regulatory Documentation
David Nguyen (J&J) – Director, Global Regulatory and Safety Sciences Lead, Oncology
Jateh Major (Merck) – Associate Director, Regulatory Affairs, Oncology
Jennifer Dudinak (Roche) – Senior Vice President, Head of Global Regulatory Sciences
Kenneth Hu (Sanofi) – Associate Director, Global Regulatory Sciences, Oncology
Matthew Wong (Daiichi-Sankyo) – Executive Director, Global Regulatory Strategy, Hematology Oncology
Nicole Stoka (Novartis) – Associate Director, US Commercial Regulatory Affairs
Omar Khalid (Allergan) – Executive Director, Global Regulatory Strategy & Cross Therapeutic Area Excellence
Shih-Yi Kim (J&J) – Executive Director, Global Regulatory Strategy Team Leader for Immunology

Global Business Operations

Kate Bender (Novartis) – Senior Director, Investor Relations

Clinical

Bryan Campbell (Novartis) – Senior Vice President, Drug Development Strategy & Innovation
Gabrielle Guancione (Merck) – Associate Director, Global Clinical Scientist, Late Hematology, Oncology & Cell Therapy
Jennifer Han (Novartis) – Associate Director, Global Clinical Scientist, Early Hematology, Oncology & Cell Therapy
Jennifer Poon (Merck) – Director, Clinical Center of Excellence Lead
Jesse Siegel (Merck) – Director, Clinical Collaboration Lead
Joseph Fiore (Merck) – Vice President, Global Program Lead, Targeted Therapy
Julia Spiridigliozzi (Merck) – Associate Director, Global Clinical Scientist, Late Hematology, Oncology & Cell Therapy
Justin Dennie (Merck) – Director, Global Clinical Scientist, Late Hematology, Oncology & Cell Therapy
Mackenzie Minogue (J&J) – Associate Director, Global Clinical Scientist, Neuroscience

Margee Kyada (Genentech) – Associate Director, Global Clinical Scientist, Late Hematology, Oncology & Cell Therapy
Marta Molina (Bimark) – Executive Director, Global Program Lead, Early Neuroscience
Naomey Sarkis (Novartis) – Director, Global Clinical Scientist, Early Hematology, Oncology & Cell Therapy
Ronak Patel (Pfizer) – Director, Program Management
Sapna Chhagan (Novartis) – Executive Director, Global Clinical Science, Early Hematology/Cell Therapy & Clinical Excellence
Whitney Handy (Merck) – Associate Director, Global Clinical Scientist, Early Hematology, Oncology & Cell Therapy

HEOR

Miraj Patel (Sanofi) – Director, US Policy Research & Economics

Policy & Advocacy

Brian Lee (Sanofi) – Senior Director, Patient Advocacy

*Not an Exhaustive List

**Last Updated – August 2026



Bristol Myers Squibb Component

The Fellows will become an integral part of their respective teams and will be trained to manage a broad range of responsibilities. This fellowship program will necessitate interaction and teamwork with departments in all aspects of the corporation, such as Global Pharmacovigilance and Labeling, Sales, Medical Affairs, Marketing, Regulatory Services, Legal, Clinical Trials, Post-Marketing Clinical Research, and Health Care Channel Management. While at Bristol Myers Squibb, the Fellows will participate in various teambuilding activities and attend leadership development lectures with senior management. Key fellowship activities within Bristol Myers Squibb include:

MENTORSHIP PROGRAM

Participate in a mentorship program with senior management and fellowship alumni to discuss career development, networking, organization structure, market/industry knowledge, etc.

LUNCH AND LEARN SERIES

Attend lunch and learn series with executive sponsors and senior management to have interactive discussions.

BRISTOL MYERS SQUIBB FELLOWSHIP COMMITTEES

Lead and take part in the various fellowship committees such as: Co-Chief Fellows, Recruitment, Community Development, Professional Development, Alumni, and Scholarship committee.

